Fig. 2: Survival analysis according to HER2-positive breast cancer subtypes identified in ALTTO. | Nature Communications

Fig. 2: Survival analysis according to HER2-positive breast cancer subtypes identified in ALTTO.

From: Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial

Fig. 2

a Kaplan–Meier plot showing DRFI in ALTTO according to the 5 HER2-positive subtypes identified from the integration of NMF, k-means clustering and AIMS intrinsic subtypes. b Kaplan–Meier plot showing OS according to the 5 HER2-positive subtypes. P values (two-sided) are from log-rank test. All analyses are on N = 386 ALTTO samples (IM, N = 69; P/Met, N = 87; Mes/S, N = 76; LUM, N = 63; ERBB2-D, N = 91). CI confidence interval, DRFI distant relapse-free interval, ERBB2-D ERBB2-dependent, IM immune-enriched, LUM luminal, Mes/S mesenchymal/stroma-enriched, NMF non-negative matrix factorization, OS overall survival, P/Met proliferative/metabolic-enriched.

Back to article page